Two decades of research into the ligand-dependent modulation of the activity of the peroxisome proliferator-activated receptor γ (PPARγ) have produced a large body of structural data from single-crystal X-ray diffraction studies of PPARγ in complex with a diverse set of ligands - 3
Introduction
The peroxisome proliferator-activated receptor γ (PPARγ) is a transcription factor regulating the expression of genes involved in lipid storage and glucose expenditure, 1 but also in kidney function, 2 bone metabolism 3 and neuronal development. 4 It is the most well-studied member of the PPAR family of nuclear receptors and both ligand-dependent and ligand-independent modes of modulation of its activity have been established. Among these, the ligand-dependent modulation of PPARγ activity has been a major focus in commercial and academic drug discovery programs seeking new treatments for human metabolic diseases, such as type II diabetes mellitus and metabolic syndrome. 1 More recently, the role of PPARγ in neurodegenerative disease has received increased attention. 4, 5 Research efforts from the past two decades have produced an array of small-molecular modulators of PPARγ, whose beneficial effects on e.g. insulin sensitivity, have allowed the application of members of the thiazolidinedione (TZD) family of PPARγ agonists in a clinical setting. In parallel, however, a body of evidence has grown, describing class-wide side effects of the TZDs, such as fluid accumulation (edema), 2 increased risk of heart failure 6 and decreased bone density. 7 The origin of these side effects was recontextualized by the discovery of a ligand- cyclin-dependent kinase 5 (Cdk5), led to the regularization of the expression levels of a set of genes known to be dysregulated in obesity (including adipsin and adiponectin). Importantly, it was shown that this gene set was only a subset of the genes whose expression was regulated by the treatment of PPARγ with the TZD rosiglitazone (1) (Figure 2 ). Furthermore, the ligand MRL24 (2) inhibited phosphorylation of Ser245 (Ser273) as efficiently as rosiglitazone (1) , even though 2 is a weak agonist compared to 1, in assays measuring the transcription of chimeric PPARγ reporters or classical, adipogenesis-related PPARγ target genes. 5 By X-ray crystallographic analysis, hydrogen-deuterium exchange coupled to mass spectrometry (HDX-MS) and nuclear magnetic resonance (NMR) spectroscopy, MRL24 (2) has been shown to preferentially bind to a different site in the PPARγ ligand-binding pocket (LBP) from both its regioisomer, the potent agonist MRL20 (3) and rosiglitazone (1) . In its binding mode, MRL24
(2) did not stabilize the PPARγ C-terminal helix 12 (shown in orange, Figure 1 ). 5, 8, 9 This helix is central to the nuclear receptor activation function 2 (AF2) and to the formation of a surface binding groove for transcriptional coactivator proteins. 10 The LBP interaction patterns observed for MRL24 (2) versus MRL20 (3), which does stabilize helix 12, were thus coherent with the lower transcriptional activation observed upon treatment of PPARγ with 2. Conversely, MRL24
(2) stabilized the β-sheet region in the Ω-pocket (shown in yellow, Figure 1 ), which in turn stabilized the external loop containing Ser245, making it less available for Cdk5-mediated phosphorylation. 5, 8, 11 Recently, it was shown that a second molecule of MRL20 (3) can bind to the Ω-pocket, simultaneously with the AF2-pocket being occupied by 3 or blocked by covalent antagonists, targeting Cys285. Both double occupancy of the LBP, as well as binding to the Ω-pocket alone were demonstrated to allosterically influence transcriptional regulation by PPARγ. 9 Among the reported PPARγ modulators that display weak transcriptional induction, is also the ligand SR1664 (4) (Figure 2 ). Intriguingly, its R-enantiomer SR1663 (5) is a potent PPARγ agonist. While 4 and 5 can display nearly identical binding modes, in which both interact with the β-sheet region through their carboxylate groups, but stretch around helix 3 and into the Ω-pocket, where they differ in their interaction with Phe282 (PDB ID: 4r2u and 4r6s). 12 In the case of SR1664 (4), this interaction near completely attenuates the transcriptional induction by PPARγ, likely through a destabilization of helix 12. 12,13 A later crystallographic study revealed that SR1664 (4) can also assume an alternative binding mode in which it no longer occupies the AF2-pocket. In this structure, 4 is located in the Ω-pocket where it interacts with helix 3 and the Ω-loop (PDB ID: 5dwl).
The Given the diverse set of ligands with which PPARγ has been cocrystallized, an evaluation of the sampled conformational space using PCA could potentially provide novel insight into collective structural differences between the PPARγ complexes with the partial-and nonagonistic ligands, and those with classical agonists. A relative classification of these complexes could add to our understanding of the different modes of ligand-dependent PPARγ activation. 33 An expressed limitation of classical PCA when it comes to the biophysical relevance of the patterns of variance it can extract, concerns the projection of the dataset variance onto linear, orthogonal axes. The variances produced by protein functional dynamics may not be optimally captured in terms of linear correlations. 34, 35 Notwithstanding this, the application of PCA to biological structural data, also known as essential dynamics analysis (EDA), 35 has been used to extract key modes of protein motion. The results of these analyses have been coherent with data from other analytical techniques, and have thus contributed to the elucidation of the functional mechanics of the studied proteins. [36] [37] [38] [39] [40] [41] [42] Classically, in PCA of protein structural data, the variances of the Cartesian coordinates of a macromolecular system are analyzed (hereafter referred to as cPCA). [36] [37] [38] Other bases of data, 
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Dataset Characteristics. The PPARγ structural data was obtained from the PDB_REDO databank. 44, 45 which contains optimized and consistently refined entries from the RCSB Protein Data Bank. 46 The X-ray crystallographic data of PPARγ available in the public domain, per January 2017, comprise 155 entries, of which 134 were deemed suitable for the initial analyses, excluding point mutants, structures whose data were recorded at temperatures other than 100±10 K and structures without deposited structure factors. The latter exclusion criterion arose from the choice to obtain the X-ray crystallographic data from the PDB_REDO server. 44, 45 In the suitable structures the asymmetric units contain PPARγ as a dimer, either with another PPARγ protein or with RXRα. There are also examples of PPARγ tetramers and monomers. Some of the structures also include oligopeptides derived from the nuclear receptor-binding motifs of coactivator proteins (typically from SRC-1).
Utilized Software and Data Treatment. The PDB-files were parsed with the functions implemented in the Python software package ProDy (ver. 1.6.1), 47 which was used for the cPCA calculations. ProDy was also used for producing a PDB-file of the reference structure (apo-PPARγ, PDB ID: 2zk0, chain A) accompanied by an ordered pseudo-trajectory of the structural ensemble in DCD-format. The Visual Molecular Dynamics (VMD) software (ver. 1.9.1) 48 was used to parameterize the protein topology (CHARMM36 version, July 2012) 49 in the reference structure PDB-file and to output this structure in PSF-format. The PSF-and DCD-files were then used as inputs for the software Carma (ver. 1.4), 50, 51 which performed the dPCA. The numerical results were read back into Python and plotted using standard Python plotting functions (matplotlib, ver. 1.3.1). An in-house program written in Python was used to coordinate the efforts of the above mentioned softwares (Python, ver. 2.7.6). 52 This code is available from the corresponding author upon request. and the three C-terminal residues (475 -477) are high and only resolved in part of the dataset.
The residue selection was thus limited to the residues resolved in most of the structures, in order to achieve consistent occupancies in the analyzed datasets. The minimum occupancies of the residue selections used in the described Plotting and Structure Mapping. The plots of the distributions obtained from PCA display the analyzed structures projected along PC1 -2. In these plots, each structure (datapoint) is coloured according to structural parameters or parameters relating to their bound ligand(s), as explained in the legend of each plot. Herein, only the first two principal components (PC1-2) from the analyses are shown and discussed, as these represent the largest variances in the dataset and since trends similar to those observed along PC1-2 (vide infra) were not found among the higher PCs.
dPC1-2 were also the only dPCs that displayed multipeak distributions. Finally, aiming to provide a useful reference for other workers, the distributions along PC1/PC2, from the cPCA and dPCA of the final dataset, are presented with numbered datapoints in Figure S1 in the Supporting Information. The PDB IDs corresponding to these numbers are listed in Table S2 .
Results & Discussion
Initial Analyses of the Dataset. Initially, the entire dataset was analyzed (237 PPARγ structures from 134 entries). As can be seen in Figure 3A , a projection of these structures onto the first two principal components of the cPCA (cPC1 and cPC2), distinguishes two large clusters. These two The crystal environment, may exert a significant influence on the structural data, that in turn may skew a comparative analysis of the same protein across crystals. [56] [57] [58] Factors related to the crystallization conditions, including the presence of salts, surfactants or other additives in the crystallization buffers, endogenous ligands from protein expression systems, as well as the often recombinant nature of the PPARγ LBD itself, all influence the crystal packing. Aiming to evaluate the dependence of the structural data on these parameters, the structures of the PPARγ type A chains were projected onto their first two principal components and coloured according to their crystallographic space groups. As can be seen in Figures 3C and 3D , the crystal packing impacts on the structural data and the tightest cluster observed along cPC1 and cPC2 is reasonably well explained by its members having crystallized in the C 1 2 1 space group. cPC1 also provides some separation of the structures in the space groups P 1 2 1 1 and P 2 1 
Analyses of a Focused Dataset.
With this dataset, the distribution along dPC1 -2 provided a clearer separation of the structures than that along cPC1 -2. By colouring the three main clusters seen in Figure 4B and transferring these colours back to the distribution along cPC1 -2 ( Figure   4A ), it becomes apparent that cPC2 indeed differentiates the structures in a manner similar to dPC1, although less distinctively. While only the distributions along dPC1 -2 display obvious multipeak behaviour, the distributions along cPC1, cPC2, dPC1 and dPC2 are all non-normal, indicating that they are not likely to have been drawn from random populations. This, in turn, supports the notion that they contain relevant structural information ( Figure S3 in the Supporting
Information for more details on normality testing). In summary, cPC1 -2 appear to capture differences between the analyzed structures that involve regions of PPARγ known to be important for its transcriptional regulation. from Cluster 3, which with respect to the two previous described dihedral pairs, is part of Cluster 3. The dihedral pair φ Ser394 /ψ Gly395 is located in close proximity to the heterodimer interface and may thus influence the interaction of PPARγ with RXR. The neighbouring residue Asp396
shows two distinct orientations and appears to form an ionic bond to Arg443 on helix 10 in one of these. With respect to the cluster defined by φ Ser394 /ψ Gly395 , the most prominent orientations of Asp396/Arg443 among its members breaks this contact, and allows Arg443 to point in the direction of the C-terminal end of helix 12 ( Figures S10 and S11) . In summary, the dPCA clusters observed in the final dataset describe structural changes in areas that are plausibly related to PPARγ transcriptional regulation.
The dihedral pair containing the angle showing the largest angular dispersion, ψ Lys358 , merits further discussion. Lys358 is flanked by Arg357, Pro359 and Phe360. Of these, Arg357
can form an ionic bridge to Glu460, located near the end of helix 11. This ionic network also involves Glu276 on helix 3. This interaction pattern is present in many of the type A chains, but not in the type B chains (e.g. in apo-PPARγ, see Figure S12 in the Supporting Information).
Furthermore, the stabilization of the end of helix 11 is observed to vary markedly between apo-PPARγ and complexes with partial agonists and full agonists. 11, 63 These observations led us to hypothesize that the strength of the ionic interaction between Arg357 and Glu460 could correlate with the stability of helix 12. Indeed others have found that this ionic network is critical to the low transactivation capacity of the human PPARγ mutant Phe360Leu, found in persons suffering from familial partial lipodystrophy. 64 Therefore, the correlation of the distances between Arg357
and Glu460, and the distributions along PC1 -2 was evaluated. For this, the C α -carbons were preferred over the O-and N-atoms that directly take part in the ionic interaction, as the former are more likely to reflect the effects on the PPARγ backbone and on the overall compactness of this part of the PPARy structure. In this context it is interesting to note that the opening of the LBP circumscribed by the start of helix 3, helix 2', the helix 6 -7 loop and the end of helix 11 has been indicated as a possible ligand exit pathway in MD simulations. 65 Consequently, a short distance between Arg357 and Glu460 may be regarded as corresponding to a tightly bound ligand. As seen in Figure 5A , the distribution observed along cPC1 correlated moderately with the Arg357 -Glu460 distance, placing the structures with the shortest distances towards the right side of the distribution (cPC1 > 0). In the dPCA, on the other hand, this trend was not observed and all three clusters are populated by structures with both long and short Arg357 -Glu460 distances ( Figure 6B ). Figure 6C . Interestingly, as several of the structures that display lower B-factors, located towards the lower right side of the largest cluster in Figure 6C , do not contain ligands that appear to contact Tyr473, it is possible that the distribution along cPC1 also reflects an allosteric stabilization of helix 12. Similar correlations were not evident in the dPCA ( Figure 6 , B and D), although the leftmost cluster in Figure 6D In the same vein, the structures were coloured according to the available data on the ability of their cocrystallized ligands to inhibit the Cdk5-mediated phosphorylation of Ser245 (Ser273), denoted "pSer245" in the plots. The ligands reported to inhibit this phosphorylation are represented both among classical (full) agonists, as well as among the partial agonists/nonagonists (Table S1 in the Supporting Information). While the distributions along cPC1 and cPC2
did not provide a distinct clustering of the structures with these ligands (Figure 7 , B and C), there is however a tendency for cPC1 to separate the structures of non-TZD ligands that inhibit Ser245 (Ser273) phosphorylation (yellow points) from the TZD ligands with the same ability (orange points). No such trend was observed in the dPCA ( Figure 4B ).
Having established that the distribution of the structures along cPC1 is to some degree related to the stability of helix 12, we evaluated whether cPC1 could reflect the transcriptional activation by each ligand compared to rosiglitazone (1) . As a measure of this, we used the reported percentage of maximal activation by each ligand in chimeric PPARγ reporter assays (commonly GAL4-PPARγ hybrid acting on luciferase reporter constructs), including only series of ligands assayed in the same report. As seen in Figure 8 , several of the ligand series display internally coherent increases in transcriptional activation relative to their distribution along cPC1, the series with the amorfrutins being a notable exception. It also apparent that the levels of transcriptional activation are not comparable between each ligand series. As mentioned above in connection with the positions along cPC1 of agonists that are stronger transcriptional activators than rosiglitazone (1), this finding supports the notion that cPC1 does not directly reflect the capacity of the PPARγ-ligand complexes for transcriptional activation. 
